Related Experiment Video

Updated: Jul 3, 2025

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons
10:03

Studying Pre-formed Fibril Induced α-Synuclein Accumulation in Primary Embryonic Mouse Midbrain Dopamine Neurons

Published on: August 16, 2020

10.6K

In vitro modulation of mTOR and mGlur5 influence α-synuclein accumulation

Viktoria Xing1, Kyle Biggar2, Stephen S G Ferguson1,3

  • 1Department of Neuroscience, Carleton University, 1125 Colonel By Drive, Ottawa, ON, K1S 5B6, Canada.

Molecular Brain
|February 15, 2024
PubMed

Insights

Parkinson's disease involves alpha-synuclein aggregation. Researchers found that rapamycin and CTEP significantly reduced alpha-synuclein fibrils in neural cells, suggesting potential therapeutic strategies.

Area of Science:

  • Neuroscience
  • Cell Biology
  • Pharmacology

Background:

  • Parkinson's disease (PD) is characterized by abnormal alpha-synuclein (α-syn) aggregation, forming Lewy bodies.
  • The mTOR pathway and glutamatergic signaling are implicated in protein aggregation processes.

Purpose of the Study:

  • To investigate the effects of the mTOR inhibitor rapamycin and the mGluR5 modulator CTEP on α-syn aggregation in a cellular model of PD.
  • To explore the potential of these compounds in promoting the clearance of pathological α-syn.

Main Methods:

  • Utilized preformed α-syn fibrils and an A53T mutant α-syn adenovirus to induce aggregation in SH-SY5Y neural cells.
  • Administered rapamycin and CTEP to assess their impact on α-syn fibril levels.
  • Monitored mTOR signaling and autophagic pathway markers.

Main Results:

  • Both rapamycin and CTEP significantly reduced α-syn fibril accumulation in SH-SY5Y cells.
  • Treatment with these compounds led to decreased mTOR signaling.
  • Enhanced autophagic pathway factors were observed following treatment.

Conclusions:

  • Rapamycin and CTEP demonstrate potential as therapeutic agents for Parkinson's disease.
  • These compounds may exert their effects by promoting intracellular degradation and clearance of aggregated α-syn.
Keywords:
In vitroParkinson’s diseasemGluR5mTORα-synuclein

More Related Videos

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model08:24

A Method to Study α-Synuclein Toxicity and Aggregation Using a Humanized Yeast Model

Published on: November 25, 2022

2.2K
Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation09:16

Exogenous Administration of Microsomes-associated Alpha-synuclein Aggregates to Primary Neurons As a Powerful Cell Model of Fibrils Formation

Published on: June 26, 2018

7.6K

Related Concept Videos

mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.8K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.6K